Kite Pharma, Inc. Sustainability Profile
Kite Pharma, Inc., a leading biotechnology company headquartered in the United States, is at the forefront of cell therapy innovation. Founded in 2009, Kite has made significant strides in the development of chimeric antigen receptor (CAR) T-cell therapies, primarily targeting cancer treatment. With a strong operational presence across North America and Europe, the company focuses on harnessing the power of the immune system to combat malignancies. Kite's flagship products, including Yescarta, are distinguished by their ability to provide personalised treatment options for patients with certain types of blood cancers. The company has achieved notable recognition within the industry, establishing itself as a pioneer in the field of oncology. With a commitment to advancing cell therapy, Kite Pharma continues to shape the future of cancer treatment, positioning itself as a key player in the biopharmaceutical landscape.
DitchCarbon Score
How does Kite Pharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kite Pharma, Inc.'s score of 58 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kite Pharma, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported emissions figures. The company is a current subsidiary of Gilead Sciences, Inc., and therefore, any climate commitments or emissions data may be cascaded from its parent organisation. Kite Pharma has not outlined any specific reduction targets or initiatives in its own documentation. However, it is important to note that it inherits sustainability and climate-related initiatives from Gilead Sciences, Inc. This includes participation in various climate frameworks such as the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are associated with Gilead Sciences at the first cascade level. As a subsidiary, Kite Pharma's climate commitments and performance metrics are likely aligned with Gilead's broader sustainability goals, although specific details regarding emissions reductions or targets have not been disclosed. The absence of direct emissions data highlights the need for further transparency in reporting and commitment to climate action within the biopharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 44,754,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 36,813,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Kite Pharma, Inc.'s Industry?
How Carbon Intensive is Kite Pharma, Inc.'s Location?
Kite Pharma, Inc.'s Scope 3 Categories Breakdown
Kite Pharma, Inc.'s Scope 3 emissions, which decreased by 7% last year and increased by approximately 3% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 74% of Scope 3 emissions.
Top Scope 3 Categories
Kite Pharma, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Kite Pharma, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
